[1] |
LU J. Progress of diagnosis and treatment of systemic light chain amyloidosis[J]. J Clin Hematol, 2021, 34(3): 205-209. DOI: 10.13201/j.issn.1004-2806.2021.03.013.
路瑾. 系统性轻链型淀粉样变性的诊治进展[J]. 临床血液学杂志, 2021, 34(3): 205-209. DOI: 10.13201/j.issn.1004-2806.2021.03.013.
|
[2] |
HUANG XH, LIU ZH. The Clinical presentation and management of systemic light-chain amyloidosis in China[J]. Kidney Dis (Basel), 2016, 2(1): 1-9. DOI: 10.1159/000444287.
|
[3] |
GERTZ MA, COMENZO R, FALK RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004[J]. Am J Hematol, 2005, 79(4): 319-328. DOI: 10.1002/ajh.20381.
|
[4] |
RAJKUMAR SV, GERTZ MA, KYLE RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy[J]. Am J Med, 1998, 104(3): 232-237. DOI: 10.1016/s0002-9343(98)00037-0.
|
[5] |
CELLI BR, RUBINOW A, COHEN AS, et al. Patterns of pulmonary involvement in systemic amyloidosis[J]. Chest, 1978, 74(5): 543-547. DOI: 10.1378/chest.74.5.543.
|
[6] |
SHIENTAG LJ, CABRERA OA, PAZOUR GJ. Allelic diversity in the serum amyloid A2 gene and amyloid a amyloidosis in a breeding colony of zebra finches (taeniopygia guttata)[J]. Comp Med, 2019, 69(5): 425-431. DOI: 10.30802/AALAS-CM-18-000139.
|
[7] |
MEI JG, SHAO LJ, CAO HQ, et al. Detection and analysis of cytogenetic abnormalities in systemic AL amyloidosis[J]. Lab Med Clin, 2016, 13(24): 3463-3466. DOI: 10.3969/j.issn.1672-9455.2016.24.011.
梅建刚, 邵靓婧, 曹红琴, 等. 系统性轻链型淀粉样变性细胞遗传学异常检测分析[J]. 检验医学与临床, 2016, 13(24): 3463-3466. DOI: 10.3969/j.issn.1672-9455.2016.24.011.
|
[8] |
GUNATHILAKA ML, NIRIELLA MA, LUKE NV, et al. Possible gasoline- induced chronic liver injury due to occupational malpractice in a motor mechanic: a case report[J]. J Med Case Rep, 2017, 11(1): 179. DOI: 10.1186/s13256-017-1352-x.
|
[9] |
GERTZ MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment[J]. Am J Hematol, 2020, 95(7): 848-860. DOI: 10.1002/ajh.25819.
|
[10] |
COLOMBAT M, ALDIGIER JC, ROTHSCHILD PR, et al. New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal amyloidosis[J]. Kidney Int, 2020, 98(1): 195-208. DOI: 10.1016/j.kint.2020.03.033.
|
[11] |
SHEN ZY. Development and innovation of liver transplantation in China[J]. J Clin Hepatol, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001.
沈中阳. 中国肝移植的发展与创新[J]. 临床肝胆病杂志, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001.
|
[12] |
PALLADINI G, DISPENZIERI A, GERTZ MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes[J]. J Clin Oncol, 2012, 30(36): 4541-4549. DOI: 10.1200/JCO.2011.37.7614.
|
[13] |
GODARA A, TOSKIC D, ALBANESE J, et al. Involved free light chains < 10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis[J]. Am J Hematol, 2021, 96(1): E20-E23. DOI: 10.1002/ajh.26025.
|